Filing Flows › Comparisons › ATNM vs BCYC
Actinium Pharmaceuticals vs Bicycle Therapeutics: ATNM and BCYC compared
Actinium Pharmaceuticals is the larger company: $35.0M of revenue in its latest quarter (Q2 2026) against $34.1M for Bicycle Therapeutics (Q3 2026). Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -39.6%.
Where the money goes: ATNM and BCYC
Actinium Pharmaceuticals (ATNM) · Q2 2026
Actinium Pharmaceuticals, Q2 2026: revenue $35.0M, operating margin 78.8%, net earnings $27.9M, operating cash flow −$5.2M. The chart follows the revenue to costs, profit and cash.
Bicycle Therapeutics (BCYC) · Q3 2026
Bicycle Therapeutics, Q3 2026: revenue $34.1M (+190% year over year), operating margin -39.6%, net loss $10.5M, operating cash flow −$40.3M. The chart follows the revenue to costs, profit and cash.
| Actinium Pharmaceuticals (ATNM) | Bicycle Therapeutics (BCYC) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $35.0M | $34.1M |
| Revenue growth, Y/Y | — | +190% |
| Operating margin | 78.8% | -39.6% |
| Net earnings | $27.9M | −$10.5M |
| Net margin | 79.7% | -30.8% |
| Operating cash flow | −$5.2M | −$40.3M |
Questions
Which is bigger, Actinium Pharmaceuticals or Bicycle Therapeutics?
Actinium Pharmaceuticals is the larger company: $35.0M of revenue in its latest quarter (Q2 2026) against $34.1M for Bicycle Therapeutics (Q3 2026).
Is Actinium Pharmaceuticals or Bicycle Therapeutics growing faster?
Actinium Pharmaceuticals is more profitable, with an operating margin of 78.8% against -39.6%.
More: Actinium Pharmaceuticals earnings · how Actinium Pharmaceuticals makes money · Bicycle Therapeutics earnings · how Bicycle Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 7, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.